19,850 Shares in Pfizer Inc. (NYSE:PFE) Purchased by Arcadia Wealth Management Inc.

Arcadia Wealth Management Inc. purchased a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 19,850 shares of the biopharmaceutical company's stock, valued at approximately $527,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Rialto Wealth Management LLC acquired a new position in Pfizer in the 4th quarter worth $26,000. Clarity Asset Management Inc. purchased a new position in Pfizer in the fourth quarter valued at about $27,000. Gould Capital LLC grew its stake in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $30,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

PFE stock traded up $0.08 during midday trading on Friday, reaching $23.53. 16,642,888 shares of the stock were exchanged, compared to its average volume of 41,011,683. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $133.80 billion, a PE ratio of 16.70, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a fifty day moving average price of $23.16 and a 200 day moving average price of $25.09.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter last year, the firm posted $0.82 earnings per share. The firm's revenue was down 7.8% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.31%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on PFE. Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.